Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Suzhou
Clinical trial register · China

Clinical Trials in Suzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Beijing 6 Shanghai 4 Fuzhou 4 Changsha 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Soochow University115 Second Affiliated Hospital of Soochow University16 Capital Medical University9 Novartis Pharmaceuticals8 Takeda7 Wecare Probiotics Co., Ltd.7 Amgen6 Children's Hospital of Soochow University6 AbbVie6 BeOne Medicines5 PersonGen BioTherapeutics (Suzhou) Co., Ltd.5 Sanofi5 Eli Lilly and Company5 The First Affiliated Hospital with Nanjing Medical University4 Pfizer4 Suzhou Municipal Hospital4 Merck Sharp & Dohme LLC4 Ascentage Pharma Group Inc.4 Shanghai Zhongshan Hospital4 Huashan Hospital4 Zhao Jun3 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.3 Shanghai Jiao Tong University School of Medicine3 Peijia Medical Technology (Suzhou) Co., Ltd.3 First Affiliated Hospital of Zhejiang University3 GlaxoSmithKline3 Janssen Research & Development, LLC3 AstraZeneca3 UCB Biopharma SRL3 Chen Suning2 Hangzhou Sumgen Biotech Co., Ltd.2 Suzhou Municipal Hospital of Anhui Province2 Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd2 Triastek, lnc.2 Karyopharm Therapeutics Inc2 GeneCradle Inc2 Tasly Pharmaceutical Group Co., Ltd2 Changhai Hospital2 Innovent Biologics (Suzhou) Co. Ltd.2 Zhangjiagang First People's Hospital2 PharmaEssentia2 Sheng-Li Xue, MD2 Nanjing RegeneCore Biotech Co., Ltd.2 Yunhe Pharmaceutical (Tianjin) Co., Ltd2 Bristol-Myers Squibb2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2 Dushu Lake Hospital Affiliated to Soochow University2 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 Novo Nordisk A/S2 Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology2 CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2 Jiangsu Topcel-KH Pharmaceutical Co., Ltd.2 Soochow University2 Celgene2 Astellas Pharma Global Development, Inc.2 Suzhou Hengruihongyuan Medical Technology Co. LTD2 Sinomune Pharmaceutical Co., Ltd1 UCARsgen Biotech Limited1 Allist Pharmaceuticals, Inc.1 Abbisko Therapeutics Co, Ltd1 First Hospital of China Medical University1 H. Lundbeck A/S1 Simcere Pharmaceutical Co., Ltd1 The Fourth Affiliated Hospital of Soochow University1 Atom Therapeutics Co., Ltd1 Xuanwu Hospital, Beijing1 Xiyuan Hospital of China Academy of Chinese Medical Sciences1 Beijing InnoCare Pharma Tech Co., Ltd.1 Hangzhou PhecdaMed Co., Ltd.1 Chunshui He1 Angitia Biopharmaceuticals Guangzhou Limited1 Starna Therapeutics1 Beeline Medicines Corporation1 EMD Serono Research & Development Institute, Inc.1 Shanghai Jiatan Pharmatech Co., Ltd1 The First Affiliated Hospital of Dalian Medical University1 Beijing Tiantan Hospital1 Healthguard Biomed1 Chongqing Precision Biotech Co., Ltd1 Zhejiang Teruisi Pharmaceutical Inc.1 Akeso1 Du Zhenggui1 The Second Hospital of Anhui Medical University1 Institut de Recherches Internationales Servier1 First Affiliated Hospital of Wannan Medical College1 Nanjing Legend Biotech Co.1 Tianjin Medical University General Hospital1 Wenjun Cheng1 Gracell Biotechnologies (Shanghai) Co., Ltd.1 Children's Hospital of Fudan University1 SyMap Medical (Suzhou), Ltd.1 China Medical University, China1 Beijing Anzhen Hospital1 Alexion Pharmaceuticals, Inc.1 The Children's Hospital of Zhejiang University School of Medicine1 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.1 Chengdu Zenitar Biomedical Technology Co., Ltd1 magAssist, Inc.1 IVIEW Therapeutics Inc.1 Sellas Life Sciences Group1 Suzhou Centergene Pharmaceuticals Co.,Ltd.1 Wellizen Australia1 Hrain Biotechnology Co., Ltd.1 Hangzhou GluBio Pharmaceutical Co., Ltd.1 Fudan University1 Biogen1 Danyang Huichuang Medical Equipment Co., Ltd.1 Shenzhen Fosun Kairos Biotechnology Co., Ltd.1 Talengen Institute of Life Sciences, Shenzhen, P.R. China.1 argenx1 Jiangsu Cancer Institute & Hospital1 Shanghai Mental Health Center1 Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.1 Wangjing Hospital, China Academy of Chinese Medical Sciences1 Southeast University, China1 The Hong Kong Polytechnic University1 Telix Pharmaceuticals (Innovations) Pty Limited1 yifang zhu1 Second Affiliated Hospital, Zhejiang University, School of Medicine1 Sichuan Baili Pharmaceutical Co., Ltd.1 Shanghai Changzheng Hospital1 Dianthus Therapeutics1 First Affiliated Hospital of Guangxi Medical University1 China National Biotec Group Company Limited1 Geneplus-Beijing Co. Ltd.1 Institut de Recherches Internationales Servier (I.R.I.S.)1 Yan Zhang1 ShanShan Li1 Prince of Songkla University1 Bioverativ, a Sanofi company1 Changchun GeneScience Pharmaceutical Co., Ltd.1 Shanghai Juncell Therapeutics1 The University of Hong Kong1 Shanghai Kechow Pharma, Inc.1 Cascade Pharmaceuticals, Inc1 Chengdu New Radiomedicine Technology Co. LTD.1 Xiaoyan Shi1 Bin Gu1 Shanghai Xinzhi BioMed Co., Ltd.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 Oneness Biotech Co., Ltd.1 Boehringer Ingelheim1 Climb Bio, Inc.1 Tongji Hospital1 Shanghai East Hospital1 Shenzhen Core Medical Technology CO.,LTD.1 Anhui Provincial Hospital1 Hangzhou DAC Biotechnology Co., Ltd.1 Nanjing Broad Biopharmaceutical Ltd.1 Zeng Changhao1 Regeneron Pharmaceuticals1 Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.1 Nanjing Medical University1 Shenzhen Kexing Pharmaceutical Co., Ltd.1 Shanghai Ming Ju Biotechnology Co., Ltd.1 yuejun Liu1 Imbioray (Hangzhou) Biomedicine Co., Ltd.1 Boston Scientific Corporation1 Arnatar Therapeutics, Inc.1 Nanjing First Hospital, Nanjing Medical University1 InventisBio Co., Ltd1 Nanfang Hospital, Southern Medical University1 SciClone Pharmaceuticals1 Junbo Ge1 Zenas BioPharma (USA), LLC1 Bivision Pharmaceuticals, Inc.1 Genmab1 Hao Yonggang1 Shanghai Hengrui Pharmaceutical Co., Ltd.1 Guangzhou Lupeng Pharmaceutical Company LTD.1 Shanghai RAAS Blood Products Co., Ltd.1 Duke Kunshan University1 Lei Yunshang Group1 Suzhou Forlong Biotechnology Co., Ltd1 Clear sponsor filter
Target enrolment
to

Trials with a site in Suzhou

1 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Fuzhou, Guangzhou, Beijing, Guanzhou, Suzhou, Xi'an
2025-09-16
Rows per page Showing 1–1 of 1
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/suzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1 of those studies with a site in Suzhou that also match the filters currently applied.

How many clinical trials are recruiting in Suzhou?

1 of the 1 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suzhou), 1 studies
PhaseStudiesRecruitingShare
Phase 311100%

Most active sponsors

Lead sponsors with the most studies (Suzhou)
Lead sponsorStudiesRecruiting
argenx11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.